<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191330</url>
  </required_header>
  <id_info>
    <org_study_id>BV-EV-HF-1901</org_study_id>
    <nct_id>NCT04191330</nct_id>
  </id_info>
  <brief_title>Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors</brief_title>
  <acronym>AIM-POWER</acronym>
  <official_title>Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize Guideline Directed Heart Failure Therapy Using Wearable Sensors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biofourmis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biofourmis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this real-world, multi-center, randomized, outpatient study is to assess the&#xD;
      effectiveness of the Biofourmis cloud based BiovitalsHFTM Clinical Decision Support Platform&#xD;
      to recommend optimal titration of Guideline-Directed Medical Therapy (GDMT) for heart failure&#xD;
      with reduced ejection fraction (HFrEF) subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the effectiveness of the cloud-based BiovitalsHF®&#xD;
      Clinical Decision Support Platform to manage initiation and titration of GDMT outside of&#xD;
      normal or traditional clinical encounters. The effectives comparison will be to the current&#xD;
      standard of care for HF used in the respective clinical sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in percent of subjects at 50% target GDMT dose</measure>
    <time_frame>90 days</time_frame>
    <description>The primary endpoint will be the difference, at 90 days, between the intervention and control arm in the percentage of subjects on beta-blocker, ACEi/ARB/ or ARNI, and MRA at 50% target dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in percent of subjects at target GDMT dose</measure>
    <time_frame>90 days</time_frame>
    <description>The key secondary endpoint will be the percentage of subjects on target dose of GDMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT-proBNP</measure>
    <time_frame>90 and 365 days</time_frame>
    <description>Change in NT-proBNP, from baseline, between the control and intervention arms at day 90 and 365.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HF Hospitalizations</measure>
    <time_frame>90 days</time_frame>
    <description>The difference of HF Hospitalizations between the control and intervention arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">282</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in the Control Arm will receive standard of care as normally provided in the clinical center where the study is being conducted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the Intervention Arm will be remotely monitored for 90 days using the BiovitalsHF platform to manage initiation and titration of GDMT with and outside of normal or traditional clinical encounters.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BiovitalsHF</intervention_name>
    <description>BiovitalsHFTM is a cloud-based, Clinical Decision Support Platform that incorporates continuous physiology data from remote vital signs monitoring devices and electronic patient reported outcome (ePRO) monitoring of subjects at-home to support GDMT dose titration for HFrEF patients.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of heart failure (left ventricular ejection fraction ≤ 40%, assessed by&#xD;
             Echocardiogram, Cardiac MRI, Cardiac CT, or Nuclear Perfusion) within the past year&#xD;
&#xD;
          -  New York Heart Association (NYHA) class II-III at most recent screening assessment&#xD;
&#xD;
          -  HFrEF patients not on GDMT or HFrEF patients who are on the following:&#xD;
&#xD;
               1. Less than or equal to metoprolol succinate 50 mg daily&#xD;
&#xD;
               2. Less than or equal to carvedilol 6.25 mg po twice daily&#xD;
&#xD;
               3. Less than or equal to bisoprolol 2.5 mg po daily&#xD;
&#xD;
               4. Less than or equal to lisinopril 20 mg po daily (or equivalent ACEi dose)&#xD;
&#xD;
               5. Less than or equal to valsartan 160 mg po daily (or equivalent ARB dose)&#xD;
&#xD;
               6. Less than or equal to sacubitril/valsartan 24/26 mg po twice daily&#xD;
&#xD;
               7. Any combination of 1 - 3 and any combination of 4 - 6&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to GDMT&#xD;
&#xD;
          -  Current treatment with beta-blocker dose greater than either metoprolol 50 mg daily,&#xD;
             carvedilol 6.25 mg po twice daily, or bisoprolol 2.5 mg po daily&#xD;
&#xD;
          -  Current treatment with ACEi equivalent to greater than lisinopril 20 mg po daily&#xD;
&#xD;
          -  Current treatment with ARB equivalent to greater than valsartan 160 mg po daily&#xD;
&#xD;
          -  Current treatment with MRA&#xD;
&#xD;
          -  Current treatment at or above the 50% recommended dose level of any single or&#xD;
             combination of GDMT recommended medications&#xD;
&#xD;
          -  Subjects who are concurrently taking any combination of ACEi, ARB, or ARNI&#xD;
&#xD;
          -  Subjects who are taking more than one beta-blocker&#xD;
&#xD;
          -  Baseline creatinine &gt; 2 mg/dl or potassium level at baseline &gt; 5 mEq/L or eGFR &lt;30&#xD;
             mL/min/1.73 m2&#xD;
&#xD;
          -  Receiving dialysis at screening&#xD;
&#xD;
          -  Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) ³ 180 mm Hg&#xD;
             or diastolic BP (DBP) ³ 110 mm Hg&#xD;
&#xD;
          -  Baseline systolic blood pressure &lt;100 mmHg&#xD;
&#xD;
          -  Baseline resting heart rate &lt;65 bpm&#xD;
&#xD;
          -  History of angioedema&#xD;
&#xD;
          -  Sick sinus syndrome&#xD;
&#xD;
          -  IDDM&#xD;
&#xD;
          -  History of or on transplant list&#xD;
&#xD;
          -  Left ventricular assist device&#xD;
&#xD;
          -  Implantable cardioverter-defibrillator (ICD)&#xD;
&#xD;
          -  Permanent Pacemaker (PPM)&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Active wheezing on physical exam&#xD;
&#xD;
          -  Severe COPD&#xD;
&#xD;
          -  Home oxygen use&#xD;
&#xD;
          -  Diagnosed cirrhosis or moderate hepatic impairment&#xD;
&#xD;
          -  Malignancy except non-melanoma skin cancers, cervical or breast ductal carcinoma in&#xD;
             situ within the last 5 years&#xD;
&#xD;
          -  Hospitalization for any reason other than heart failure within the 30 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Currently receiving hospice or comfort care&#xD;
&#xD;
          -  Currently participating or receiving treatment in an investigational device or drug&#xD;
             study or any other investigational procedures while participating in this study or&#xD;
             having participated in a study less than 30 days prior to screening are excluded&#xD;
&#xD;
          -  Subject unable to connect to internet from their domicile (either via cellular,&#xD;
             land-line phone or cable service)&#xD;
&#xD;
          -  Subject unable to independently navigate and operate smartphone applications&#xD;
&#xD;
          -  Subject not proficient with written and spoken English&#xD;
&#xD;
          -  Subject determined likely to be non-compliant by physician/HCP&#xD;
&#xD;
          -  Subject likely to not be available to complete all protocol-required study visits or&#xD;
             procedures, and/or to comply with all required study procedures (e.g., Clinical&#xD;
             Outcome Assessments) to the best of the subject and investigator's knowledge.&#xD;
&#xD;
          -  History or evidence of any other clinically significant disorder, condition or disease&#xD;
             (with the exception of those outlined above) that, in the opinion of the investigator&#xD;
             or Biofourmis medical monitor, if consulted, would pose a risk to subject safety or&#xD;
             interfere with the study evaluation, procedures or completion.&#xD;
&#xD;
          -  Subject has diminished decision making capability&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akshay Desai, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Womens Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maulik Majmudar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biofourmis Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trace Brookins</last_name>
    <phone>919.355.8221</phone>
    <email>trace@biofourmis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Appalachian Cardiovascular Associates</name>
      <address>
        <city>Fort Payne</city>
        <state>Alabama</state>
        <zip>35967</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjeev Saxena, MD</last_name>
      <phone>256-997-9200</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

